New cancer test receives FDA approval

Recent advancements in the health sciences have paved a new path to screening for recurring breast cancer with more accuracy. The Food and Drug Administration recently approved a microarray genetic test, called MammaPrint, that is designed to determine the likelihood of early-stage breast cancer recurrence within 5 to 10 years of initial treatment. It is […]